“intellia-therapeutics” Archives

in
Entry Author Date Location
Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More 06/12/20 National
Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact 06/01/20 New York
Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s 12/17/19 Boston
Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs 09/27/19 Boston
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
Precision Bio’s IPO Raises $126M for Pipeline of Gene-Edited Drugs 03/27/19 Raleigh Durham
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More 02/08/19 National
New CRISPR Fight: Old Friends Intellia, Caribou in License Dispute 02/06/19 San Francisco
Pre-Existing Immunity to CRISPR Found in 96% of People in Study 10/29/18 Boston
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More 07/20/18 National
New Study Shows CRISPR Can Delete Big Chunks of DNA 07/16/18 National
Bio Roundup: Not-BIO Party Foul, CRISPR Drama, Sickle Cell Updates 06/15/18 National
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells 06/11/18 National
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M 05/14/18 Boston
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost 02/22/18 San Francisco
Arrowhead Plans Return to Clinic With New Study of Hep B Drug 02/16/18 Wisconsin
CRISPR Recovery? “Furor” Briefly Snips $500M From Companies’ Values 01/12/18 Boston
Gene Therapy 2.0: New Startups Aim to Fine-Tune Gene Delivery and Control 01/04/18 Boston
CRISPR Could Soon Charge into Hearing Loss Drug Race, New Study Suggests 12/20/17 National
KSQ Bets on CRISPR-Juiced Drug Discovery With $76M & Ex-Genzyme CEO 10/02/17 Boston
Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist 08/01/17 Boston
CRISPR Pioneer Zhang Preaches Extra Caution In Human Gene Editing 07/31/17 Boston
Bio Roundup: ASCO Combo Frenzy, Maine’s Free DNA Tests, Sema4 & More 06/02/17 National
First Trial in Sight, Editas Cuts $90M Eye Drug Deal With Allergan 03/14/17 Boston
Patent Judges’ CRISPR Ruling For Broad Leaves Daylight For Berkeley 02/15/17 Boston
VC Activity in Boston Dipped in 2016; Here Are the Top 10 Deals & Exits 01/11/17 Boston
As Its Rivals Team Up, Editas Buys Next-Gen CRISPR From Old Friends 12/19/16 Boston
Boston’s Life Science Disruptors: The Photos 10/27/16 Boston
CRISPR Therapeutics Raises $56M In IPO, Half Its Rivals’ Haul 10/18/16 Boston
Last Chance to Save on Boston’s Life Science Disruptors on 10/20 10/17/16 Boston
Page 1 of 3 next page »